DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Prediction of Immunotherapeutic Effect of Advanced Non-small Cell Lung Cancer

Not Applicable

Conditions: NSCLC Patients

Interventions: Drug: nafulizumab
Drug: pabolizumab

First Posted Date: 2020-06-11

Last Posted Date: 2020-06-11

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT04427475

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

Phase 2

Conditions: PFS

Interventions: Drug: Gefitinib
Drug: Bevacizumab Combined With Gefitinib

First Posted Date: 2020-06-11

Last Posted Date: 2020-06-12

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT04425187

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients

Phase 2

Active, not recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: epirubicin hydrochloride
Drug: Cyclophosphamide
Drug: Albumin bound paclitaxel
Drug: Toripalimab

First Posted Date: 2020-06-05

Last Posted Date: 2024-05-21

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT04418154

Locations: 🇨🇳
Shanghai Cancer Center, Fudan University, Shanghai, Shanghai, China

A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT)

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Procedure: Metastasectomy for the metastatic sites

First Posted Date: 2020-06-04

Last Posted Date: 2020-06-04

Lead Sponsor: Fudan University

Target Recruit Count: 172

Registration Number: NCT04413409

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer

Phase 3

Recruiting

Conditions: Surgery
Metastatic Colon Cancer

Interventions: Procedure: resection of primary tumor
Drug: XELOX
Drug: mFOLFOX6

First Posted Date: 2020-06-04

Last Posted Date: 2020-06-04

Lead Sponsor: Fudan University

Target Recruit Count: 627

Registration Number: NCT04416854

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer

Phase 2

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Capecitabine
Drug: Irinotecan
Radiation: Neoadjuvant Radiotherapy

First Posted Date: 2020-06-02

Last Posted Date: 2020-06-02

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT04411537

Locations: 🇨🇳
Zhen Zhang, Shanghai, Shanghai, China

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Phase 2

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Capecitabine
Drug: Irinotecan
Radiation: Neoadjuvant Radiotherapy

First Posted Date: 2020-06-02

Last Posted Date: 2020-06-02

Lead Sponsor: Fudan University

Target Recruit Count: 50

Registration Number: NCT04411524

Locations: 🇨🇳
Zhen Zhang, Shanghai, Shanghai, China

Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

Phase 3

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Traditional Chinese Medicine Formulation
Drug: Placebo Formulation

First Posted Date: 2020-05-27

Last Posted Date: 2020-06-01

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT04403529

Locations: 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.

Phase 2

Active, not recruiting

Conditions: TNBC - Triple-Negative Breast Cancer

First Posted Date: 2020-05-20

Last Posted Date: 2023-12-22

Lead Sponsor: Fudan University

Target Recruit Count: 139

Registration Number: NCT04395989

Locations: 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

A Study of Chinese Herbal Compound Dendrobium Huoshanense Granules in NCRT for Patients With Locally Advanced Rectal Cancer

Phase 2

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: Dendrobium Huoshanense Granules
Radiation: Pelvic Radiation
Drug: Capecitabine
Other: Placebo
Drug: Irinotecan

First Posted Date: 2020-05-19

Last Posted Date: 2020-05-19

Lead Sponsor: Fudan University

Target Recruit Count: 210

Registration Number: NCT04394598

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy